Severe antiphospholipid antibody syndrome – response to plasmapheresis and rituximab

Paraskevi GkogkolouDepartment of Dermatology, University Hospital of Münster, Münster, Germany

Jan EhrchenDepartment of Dermatology, University Hospital of Münster, Münster, Germany

Tobias GoergeDepartment of Dermatology, University Hospital of Münster, Münster, GermanyCorrespondence[email protected]

http://orcid.org/0000-0002-3631-8841

References

Chaturvedi S, McCrae KR. Recent advances in the antiphospholipid antibody syndrome. Curr Opin Hematol. 2014;21:371–9.
PubMed Web of Science ®Google Scholar
Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.
PubMed Web of Science ®Google Scholar
Nayer A, Ortega LM. Catastrophic antiphospholipid syndrome: a clinical review. J Nephropathol. 2014;3:9–17.
PubMedGoogle Scholar
Erkan D, Vega J, Ramón G, et al. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013;65:464–71.
PubMed Web of Science ®Google Scholar
Berman H, Rodríguez-Pintó I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12:1085–90.
PubMed Web of Science ®Google Scholar
Costa R, Fazal S, Kaplan RB, et al. Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis. Clin Rheumatol. 2013;32(Suppl 1):S79–S82.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Severe antiphospholipid antibody syndrome – response to plasmapheresis and rituximab

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Severe antiphospholipid antibody syndrome – response to plasmapheresis and rituximab

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date